{
    "organizations": [],
    "uuid": "a84d11486b2837f40ccc13fce15c6da0e727ca2b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-esperion-therapeutics-says-bempedo/brief-esperion-therapeutics-says-bempedoic-acid-observed-to-be-safe-well-tolerated-in-phase-3-study-idUSB8N1KT00N",
    "ord_in_thread": 0,
    "title": "BRIEF-Esperion Therapeutics Says Bempedoic Acid Observed To Be Safe & Well-Tolerated In Phase 3 Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7 (Reuters) - Esperion Therapeutics Inc:\n* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID\n* ESPERION THERAPEUTICS SAYS PHASE 3 STUDY OF BEMPEDOIC ACID MET PRIMARY ENDPOINT WITH 28% LOW DENSITY LIPOPROTEIN CHOLESTEROL LOWERING\n* ESPERION THERAPEUTICS SAYS BEMPEDOIC ACID OBSERVED TO BE SAFE AND WELL-TOLERATED IN THE PHASE 3 STUDY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-07T20:45:00.000+02:00",
    "crawled": "2018-03-08T17:38:10.036+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "esperion",
        "therapeutic",
        "inc",
        "esperion",
        "announces",
        "positive",
        "result",
        "first",
        "pivotal",
        "phase",
        "study",
        "bempedoic",
        "acid",
        "esperion",
        "therapeutic",
        "say",
        "phase",
        "study",
        "bempedoic",
        "acid",
        "met",
        "primary",
        "endpoint",
        "low",
        "density",
        "lipoprotein",
        "cholesterol",
        "lowering",
        "esperion",
        "therapeutic",
        "say",
        "bempedoic",
        "acid",
        "observed",
        "safe",
        "phase",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}